Search

everythinglearnresearchcommunity

for

Search:↓

Topical immunotherapy with DPCP led to some hair regrowth in most pediatric alopecia areata patients, especially those with milder cases and longer treatment.

Topical diphencyprone helped regrow hair in mice and rats with a condition similar to human hair loss.

Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.

Method B with propylene glycol is better for stable low-concentration DPCP solutions for alopecia areata.

DCPA is a chronic leg infection often related to Staphylococcus aureus, affecting mostly young men in India.

DPC-Exos can help regenerate hair follicles and heal wounds by activating the Wnt/β-catenin pathway.

A specific gene variant is linked to heart disease, increased heart muscle, curly hair, and thick skin on palms and soles.

Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.

Three characteristics of plasmacytoid dendritic cells help tell apart lupus-related hair loss from LPP.

ATP-sensitive potassium channels are important for hair growth.

Diphencyprone helped most patients with alopecia areata regrow some hair.

DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.

CRABP1 boosts hair cell growth in Hu sheep by affecting key genes.

PRC1 is essential for proper skin development and stem cell formation by controlling gene activity.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

PDCD4 is important for controlling skin cell growth and healing.

Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.

CCCA may involve the PD1/PDL1 pathway and increased caspase 3, leading to permanent hair loss.

Home-use treatment for severe alopecia areata is as effective as office-use but costs half as much.

CCCA and LPP may be related hair loss conditions influenced by genetics and environment, needing early treatment.

A young woman with severe symptoms of CPAN improved with intensive treatment but needed a leg amputation.

Pseudopelade of Brocq is a unique hair loss condition, but its cause and development are still not fully understood.

Increasing PDCD4 protein may help prevent or treat some skin cancers.

Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.

DCPA is a chronic skin condition affecting the legs, often misdiagnosed, and needs more research for better understanding and treatment.

DCP in isopropanol is better tolerated for treating alopecia areata.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

PDRN helps repair tissue and improve wound healing with a high safety profile.